A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Vesencumab (Primary) ; Bevacizumab; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 02 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2010 Seven patients had been enrolled in two dose cohorts by June 2010, according to information presented at the Annual Meeting of the American Society of Clinical Oncology (aSCO-2010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top